Please use this identifier to cite or link to this item:
https://repository.ucc.edu.co/handle/20.500.12494/41505
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Zapata Builes, Wildeman | - |
dc.creator | Aguilar-Jiménez W. | - |
dc.creator | Feng Z. | - |
dc.creator | Weinberg A. | - |
dc.creator | Russo A. | - |
dc.creator | Potenza N. | - |
dc.creator | Estrada H. | - |
dc.creator | Rugeles M.T. | - |
dc.date.accessioned | 2021-12-16T22:15:34Z | - |
dc.date.available | 2021-12-16T22:15:34Z | - |
dc.date.issued | 2016 | - |
dc.identifier | https://doi.org/10.1016/j.vetmic.2016.12.039 | - |
dc.identifier.issn | 12864579 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.12494/41505 | - |
dc.description.abstract | Defensins, RNases and cytokines are present at mucosal barriers, main ports of HIV entry, and are potential mediators of the resistant phenotype exhibited by HIV-1-exposed seronegative individuals (HESN) during sexual exposure. We aimed to determine the role of soluble factors in natural resistance to HIV-1 infection. Vaginal/endocervical/oral mucosal samples were taken from 60 HESN, 60 seropositive (SP) and 61 healthy controls (HC). Human neutrophil peptide 1 (hNP-1), human beta defensin (hBD) 2 and 3, RNases, MIP-1ß and RANTES mRNA transcripts were quantified by qPCR and in vitro single-round, recombinant-based viral infectivity assay was used to evaluate the anti-HIV-1 activity of hBDs and RNases. HESN expressed significantly higher levels of hNP-1, hBDs mRNA in oral mucosa compared to HC (P < 0.05). In genital mucosa, significantly higher mRNA levels of MIP-1ß, RANTES and RNases were found in HESN compared to HC (P < 0.05). HBDs and RNases inhibit HIV-1 replication, particularly R5 at entry, reverse transcription and nuclear import of the viral life cycle. hNP-1, hBDs, MIP-1ß, RANTES and RNases, collectively could contribute to HIV-1 resistance during sexual exposure. Moreover, the inhibition of HIV-1 infection in vitro by hBDs and RNases suggests that they may be exploited as potential antiretrovirals. © 2015 Institut Pasteur. | es |
dc.description.provenance | Made available in DSpace on 2021-12-16T22:15:34Z (GMT). No. of bitstreams: 0 Previous issue date: 2016 | en |
dc.format.extent | 219-211 | es |
dc.publisher | Elsevier Masson SAS | es |
dc.relation.ispartof | MICROBES AND INFECTION | es |
dc.subject | angiogenin | es |
dc.subject | beta defensin 2 | es |
dc.subject | beta defensin 3 | es |
dc.subject | macrophage inflammatory protein 1beta | es |
dc.subject | maraviroc | es |
dc.subject | messenger RNA | es |
dc.subject | n [4 [[[6,7 dihydro 2 (4 methylphenyl) 5h benzocyclohepten 8 yl]carbonyl]amino]benzyl] n,n dimethyl 2h tetrahydropyran 4 aminium chloride | es |
dc.subject | neutrophil peptide 1 | es |
dc.subject | plerixafor | es |
dc.subject | protein | es |
dc.subject | RANTES | es |
dc.subject | ribonuclease | es |
dc.subject | unclassified drug | es |
dc.subject | zidovudine | es |
dc.subject | immunologic factor | es |
dc.subject | adult | es |
dc.subject | antiviral activity | es |
dc.subject | Article | es |
dc.subject | CD4+ T lymphocyte | es |
dc.subject | controlled study | es |
dc.subject | dose response | es |
dc.subject | human | es |
dc.subject | Human immunodeficiency virus 1 | es |
dc.subject | Human immunodeficiency virus 1 infection | es |
dc.subject | in vitro study | es |
dc.subject | in vivo study | es |
dc.subject | innate immunity | es |
dc.subject | life cycle | es |
dc.subject | major clinical study | es |
dc.subject | mouth mucosa | es |
dc.subject | polymerase chain reaction | es |
dc.subject | priority journal | es |
dc.subject | protein analysis | es |
dc.subject | protein expression | es |
dc.subject | protein function | es |
dc.subject | quantitative analysis | es |
dc.subject | reverse transcription | es |
dc.subject | sexual intercourse | es |
dc.subject | uterine cervix mucosa | es |
dc.subject | vagina mucosa | es |
dc.subject | viral tropism | es |
dc.subject | virus entry | es |
dc.subject | virus infectivity | es |
dc.subject | virus inhibition | es |
dc.subject | virus load | es |
dc.subject | virus replication | es |
dc.subject | virus resistance | es |
dc.subject | virus strain | es |
dc.subject | adolescent | es |
dc.subject | disease resistance | es |
dc.subject | fema | es |
dc.title | Identification of innate immune antiretroviral factors during in vivo and in vitro exposure to HIV-1 | es |
dc.type | Artículo | - |
dc.creator.mail | wildeman.zapatab@campusucc.edu.co | es |
dc.identifier.bibliographicCitation | Zapata W,Aguilar W,Feng Z,Weinberg A,Russo A,Potenza N,Estrada H,Rugeles MT. Identification of innate immune antiretroviral factors during in vivo and in vitro exposure to HIV-1. MICROBES AND INFECTION. 2016. 18. (3):p. 211-219. . | es |
dc.rights.accessRights | Desconocido | es |
dc.description.orcid | 0000-0002-7351-8738 | es |
Appears in Collections: | Artículos Científicos |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.